 MIC is a key oncogenic driver in many different types of cancer, but it also provides certain vulnerabilities that can be exploited for targeted pharmaceutical interventions. One such vulnerability is that MIC overexpressing cells are sensitive to drugs that block mitochondrial respiration. Researchers have found that a drug called IACS-010759 can be used to treat these cells, which leads to increased oxidative stress and decreased levels of reduced glutathion, ultimately resulting in cell death. Additionally, researchers have discovered that when combined with high doses of ascorbate, vitamin C, IACS-010759 has even more potent anti-cancer effects. These findings suggest that combining IACS-010759 with high doses of ascorbate may be beneficial for treating MYC-driven cancers. This article was authored by Giulio Donotti, Paola Niccoli, Alice Androverettia, and others.